Myo-inositol for Mood: What 3 Studies Show (2026 Evidence Grade)
Not according to the controlled evidence we reviewed: in the one placebo-controlled trial in this set, 42.1% of 38 adults with trichotillomania responded to 10 weeks of inositol versus 31.6% on placebo, a non-significant difference (RR 1.33, 95% CI 0.57 to 3.11) rated low-certainty evidence (PMID 34582562). Mood is where myo-inositol’s marketing drifts furthest from its data, and the HYPE Index scores this claim at 70, a Significant Evidence Gap, the highest of the ten claims graded on the myo-inositol review hub. This page is a claim autopsy: what the three studies we reviewed for this question found, and where the story left the evidence behind.
Presented By Our Partners
Where the mood claim came from
Inositol is a precursor of phosphatidylinositol signaling downstream of serotonin receptors, and lithium is thought to act partly by depleting it. That mechanism made inositol a plausible antidepressant and anti-panic candidate in psychiatric research decades ago, at very high doses, often 12 to 18 g per day. The claim then travelled: from psychiatric trials in diagnosed patients to wellness influencers selling “myo-inositol for anxiety” at 2 to 4 g per day to healthy adults with everyday stress. The dose changed, the population changed, and the evidence did not follow.
| Study | Design and population | Finding |
|---|---|---|
| PMID 34582562 | Cochrane review of 12 medication trials in trichotillomania; one 38-person placebo-controlled trial of inositol for 10 weeks | Response 42.1% versus 31.6%, RR 1.33 (95% CI 0.57 to 3.11), low certainty, no difference from placebo |
| PMID 35608150 | Systematic review of 60 studies (33 observational, 27 interventional) of diet and supplements in bipolar disorder | Inositol effects on symptoms variable and mainly non-significant; omega-3, seafood, folic acid and zinc associated with improvement |
| PMID 42462928 | Open-label 6-week study in children and adolescents aged 5 to 17 with emotional dysregulation; inositol 1,000 to 2,000 mg daily plus omega-3 versus N-acetylcysteine | Modest improvement in mania and depression scores in both groups, no between-group difference, no placebo |
What each study actually shows
The trichotillomania trial is the only placebo-controlled test of inositol in this set. Trichotillomania is an obsessive-compulsive-related condition, not depression or generalized anxiety, and the result was a non-significant 10.5 percentage point difference in response in 38 people (PMID 34582562). The dose was not stated in the abstract. The bipolar review did not pool data; it surveyed 60 studies and found inositol’s effects on bipolar symptoms variable and mainly non-significant, in contrast to omega-3 fatty acids and several dietary factors that were associated with improvement (PMID 35608150). The 2026 pediatric study is the newest and the weakest design: open label, no placebo, and inositol was given together with omega-3 providing 1,020 mg EPA, so any within-group improvement in depression scores cannot be attributed to inositol at all (PMID 42462928). Its sample size was not stated in the abstract.
Featured Partner
Invest in the Infrastructure Behind Modern Medicine
As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.
Learn More →
Why this claim scores highest on the HYPE Index
Under the HYPE Index method described at HDAI’s methodology page, hype is the distance between a claim as sold and the calibration its evidence supports. On the E axis, expectation versus evidence, mood marketing persists despite a null placebo-controlled trial and a mainly non-significant literature in bipolar disorder, which is the clearest update failure in the profile. On the H axis, the hypothesis has been tested and has not delivered, a failed analogue the market ignores. On the Y axis, none of the three studies enrolled the general wellness population the claim targets. The composite of 70 is editorial commentary on that gap, not a statement about anyone’s intent.
What we do not know
None of the studies we reviewed tested inositol alone in a diagnosed anxiety disorder, in unipolar depression as a primary outcome, or in healthy adults with everyday stress, and none used the 2 to 4 g doses now sold for mood. The older high-dose psychiatric trials that started this story are not in the set we graded, so this page cannot speak to them; it can only say that nothing in the three studies here supports the claim as marketed.
Doses used in studies
These are doses reported by the named sources, not recommendations.
| Source | Dose as reported | Context |
|---|---|---|
| PMID 42462928 | Inositol 1,000 to 2,000 mg daily for 6 weeks, open label, with omega-3 providing 1,020 mg EPA | Children and adolescents aged 5 to 17 with emotional dysregulation |
| PMID 34582562 | Inositol for 10 weeks; dose not stated in abstract | 38 adults with trichotillomania, placebo-controlled |
Back to the myo-inositol review hub, where the stress and quality-of-life claim is graded separately. The interactions table there covers bipolar disorder, lithium and serotonergic antidepressants. For how HDAI grades a supplement whose marketing outran its trials in a different category, see the NMN review.
Similar Posts
The 30 Plants a Week Rule: How Microbiome Diversity Became 2026’s Most Practical Nutrition Target
A quiet conclusion has emerged from microbiome science: variety, not any single superfood, predicts a resilient gut and lower systemic inflammation. Inside the American Gut Project finding that launched the…
The Shot That Regrows Knee Cartilage: Inside the 15-PGDH Breakthrough
Stanford researchers switched off a single age-related enzyme and watched worn knee cartilage grow back. It happened in old mice, in injured mice, and in human tissue removed during knee…
One in Three Americans Now Ask AI About Their Health. Here’s What the Data Reveals.
A Rock Health survey of 8,000 Americans and a Microsoft analysis of 500,000 Copilot conversations reveal a seismic shift in how people navigate symptoms, treatments, and the healthcare system itself….
The Daily Rounds: Longevity & Health Care Brief | June 9, 2026
🤖 Pancreatic Cancer Gets Its Biggest Breakthrough in a Decade: Daraxonrasib nearly doubles median survival versus chemotherapy, earning a standing ovation at ASCO 2026 and advancing toward FDA submission. 🦠 Gut Bacteria Talk to Your Immune System in a Newly Discovered Molecular Language: A Helmholtz Munich team maps over 1,000 direct protein interactions between common gut bacteria and human cells, fundamentally reframing how the microbiome shapes immunity. ❤️ Night Owl Cardiac Risk Is Mostly Behavioral, Not Biological: AHA research shows the elevated heart disease risk for evening types is largely explained by modifiable lifestyle factors, making it genuinely actionable. 💪 Grip Strength Is a Mortality Predictor for Older Women, Period: The largest study of its kind confirms muscle strength protects women over 60 from early death regardless of how much aerobic exercise they do. 🥗 GLP-1 Success Depends on What You Keep, Not Just What You Lose: A new clinical framework urges practitioners to prioritize muscle preservation alongside weight loss in GLP-1 therapy to protect long-term function and metabolic health.
What Are Somatic Mutations? A Plain-English Guide to the DNA Changes Happening Inside You Right Now
Somatic mutations are DNA changes that happen in your body’s cells throughout life, not at conception. A plain-English guide to what they are, how they arise, why most of them…
Fit3D ProScanner: Commercial 3D Body Scanner with Wellness Score and Health Risk Assessment
Every year, millions of gym members quit because they cannot see progress. A 35-second 3D scan changes what “progress” looks like. Presented By Our Partners The fitness industry’s retention problem…
